MedNews

  • Drug Industry News
  • FDA News & Alerts
  • Health & Medical News
You are here: Home / Archives for FDA News & Alerts

FDA Warns Consumers Not to Eat Raw Oysters Harvested from Hood Canal Area 4 in Washington State

September 26, 2011 By MedNews Leave a Comment

Oyster recall affects 23 states

Fast Facts
• The U.S. Food and Drug Administration is warning consumers not to eat raw oysters harvested from an area of Hood Canal in Washington State following an outbreak of illness in that state caused by Vibrio parahaemolyticus bacteria.

• Raw oysters harvested from “growing area 4” in Hood Canal from August 30 to September 19 have been linked to three confirmed and two possible cases of Vibrio parahaemolyticus illness.

• All ill persons reported consumption of raw oysters.

• There have been no reports of hospitalizations or deaths resulting from consuming the oysters.

• The Washington State Department of Health has closed the growing area associated with the illnesses. Commercial oyster harvesters and dealers who obtained oysters from this growing area have initiated a recall and notified their commercial customers in affected states of the recall.

• Shipping and other records provided by Washington State indicate that oysters harvested from this area were distributed to establishments in 23 states and four foreign countries. Washington State authorities have notified those states involved of the recall.

• Those who have recently purchased oysters should check with the place of purchase and ask if they were harvested from the affected growing area.

What is the problem?
Raw oysters harvested and shipped from Hood Canal Area 4 in Washington State between August 30 and September 19 have been linked to illnesses caused by Vibrio parahaemolyticus bacteria.

What are the symptoms of Vibrio illness?
Illness is typically characterized by nausea, vomiting, and diarrhea. The symptoms begin from a few hours up to five days after consumption of raw or undercooked seafood, particularly shellfish, or after ingestion of surface waters.

Who is at risk?
Persons at risk are those who traveled to Washington State and consumed oysters that were harvested from Hood Canal Area 4 or who purchased oysters in a state to which these oysters were distributed and ate them.  Individuals with weakened immune systems, including people affected by AIDS, chronic alcohol abuse, liver, stomach, or blood disorders, cancer, diabetes, or kidney disease can be more susceptible to vibrio illness and should avoid eating raw oysters, regardless of where they are harvested.

What Do Consumers Need To Do?
Consumers in the affected states should inquire of the retailer, restaurant, or other facility about the source of the oysters offered for purchase. If the oysters were definitely or possibly harvested from Hood Canal Area 4 in Washington State, and have not yet been consumed, they should not be eaten. If the oysters were already consumed and no one became ill, no action is needed. If you develop a diarrheal illness within a week after consuming raw or undercooked shellfish, see your healthcare provider and inform the provider about this exposure.

Where Were the Oysters Distributed?
Records obtained by Washington State health officials indicate that raw oysters from this area of the Hood Canal in Washington State were distributed to 23 states: Alaska, Arizona, California, Colorado, Connecticut, Florida, Hawaii, Illinois, Indiana, Maryland, Minnesota, Mississippi, Missouri, New Jersey, New York, North Carolina, Ohio, Oregon, Pennsylvania, Texas, Virginia, Utah, and Washington. Oysters from this area were also distributed internationally to the People’s Republic of China, Indonesia, Thailand and Taiwan.

What is Being Done about the Problem?
The Washington State Department of Health has closed Area 4 of Hood Canal to shellfish harvesting. All product harvested and shipped between August 30 and September 19 has been recalled. Washington State has notified all other states where product was shipped that they should hold and destroy product.

Who Should be Contacted?
The FDA encourages consumers with questions about seafood safety to call 1-888-SAFEFOOD

Source: FDA

Filed Under: FDA News & Alerts Tagged With: Hood Canal, Oyster Recall, Vibrio parahaemolyticus, Washington

Lymphoma Risk From TNF Blockers in Teens, Says FDA

April 14, 2011 By MedNews 1 Comment

The U.S. Food and Drug Administration (FDA) continues to receive reports of a rare cancer of white blood cells (known as Hepatosplenic T-Cell Lymphoma or HSTCL), primarily in adolescents and young adults being treated for Crohn’s disease and ulcerative colitis with medicines known as tumor necrosis factor (TNF) blockers, as well as with azathioprine, and/or mercaptopurine.

Crohn’s disease and ulcerative colitis cause inflammation of the digestive system. Common symptoms are pain in the abdomen, cramps, and diarrhea. Bleeding from the rectum, weight loss, joint pain, skin problems and fever also may occur. Children with the disease may have growth problems, develop intestinal blockage, and experience malnutrition. [Read more…]

Filed Under: FDA News & Alerts Tagged With: adalimumab, azathioprine, Crohn's Disease, Hepatosplenic T-Cell Lymphoma, HSTCL, Humira, infliximab, Lymphoma, mercaptopurine, Remicade, TNF Blockers

Dengue Fever Diagnostic Test Approved for Marketing

April 8, 2011 By MedNews Leave a Comment

The U.S. Food and Drug Administration (FDA) today allowed marketing of the first test to help diagnose people with signs and symptoms of dengue fever or dengue hemorrhagic fever, a leading cause of illness and death in the tropics and subtropics.

The dengue virus is transmitted to humans by the bite of an infected Aedes mosquito. As many as 100 million people worldwide are infected by the virus each year, according to the U.S. Centers for Disease Control and Prevention (CDC).

Symptoms of dengue fever include high fever, severe headache, severe pain behind the eyes, joint pain, muscle and bone pain, rash and mild bleeding involving the nose or gums, and easy bruising. [Read more…]

Filed Under: FDA News & Alerts Tagged With: Alberto Gutierrez, Dengue Fever, Dengue Fever Diagnostic Test, Dengue Hemorrhagic Fever, DENV Detect IgM Capture ELISA

Company Recalls Hazelnuts Linked to E. Coli

March 5, 2011 By MedNews Leave a Comment

DeFranco & Sons of Los Angeles, Calif. is voluntarily recalling bulk and consumer-packaged in-shell hazelnuts and mixed-nut products containing in-shell hazelnuts. The recalled products are linked to seven cases of Escherichia coli O157:H7 in Michigan, Minnesota and Wisconsin and may cause serious illness.

Consumers who have purchased bulk in-shell hazelnuts or mixed-nut products containing in-shell hazelnuts should check with the retailer to determine if they are subject to the recall, or throw the nuts away. [Read more…]

Filed Under: FDA News & Alerts Tagged With: DeFranco & Sons, Food Recalls, Hazelnuts, Sunripe

Epilepsy Drug Topiramate May Increase Birth Defect Risk

March 4, 2011 By MedNews 2 Comments

New data suggest that the drug Topamax and its generic versions (topiramate) increase the risk for the birth defects cleft lip and cleft palate in babies born to women who use the medication during pregnancy, the U.S. Food and Drug Administration (FDA) said today.

Before prescribing topiramate, approved to treat certain types of seizures in people who have epilepsy, health care professionals should warn patients of childbearing age about the potential hazard to the fetus if a woman becomes pregnant while using the drug.

Topiramate also is approved to prevent migraine headaches, but not to relieve the pain of migraines.

“Health care professionals should carefully consider the benefits and risks of topiramate when prescribing it to women of childbearing age,” said Russell Katz, M.D., director of the Division of Neurology Products in the FDA’s Center for Drug Evaluation and Research. “Alternative medications that have a lower risk of birth defects should be considered.”

[Read more…]

Filed Under: Epilepsy, FDA News & Alerts Tagged With: Topamax, topiramate

Hypertension Drug Letairis Gets New Boxed Warning: No Monthly Liver Enyme Test Required

March 4, 2011 By MedNews Leave a Comment

Monthly liver enzyme tests are no longer required for those taking Letairis tablets (ambrisentan), according to the U.S. Food and Drug Administration (FDA). The drug is used to treat high blood pressure in the vessels that carry blood to the lungs (pulmonary arterial hypertension, or PAH).

Citing data from clinical trials and post-market reports, the FDA said that the drug poses only a low risk of liver injury. Information related to potential serious liver injury and the need to monitor for such serious injury is being removed from the drug’s boxed warning. [Read more…]

Filed Under: FDA News & Alerts, High Blood Pressure Tagged With: ambrisentan, endothelin receptor antagonists, Gilead Sciences, high blood pressure, hypertension, letairis, Mary Ross Southworth, pulmonary arterial hypertension, RiskMAP

New Drug (Daliresp) to Treat COPD Approved

March 1, 2011 By MedNews Leave a Comment

The U.S. Food and Drug Administration approved roflumilast (Daliresp), a pill taken daily to decrease the frequency of flare-ups  or worsening of symptoms from severe chronic obstructive pulmonary disease (COPD).

COPD is a serious lung disease that makes breathing difficult. Symptoms can include breathlessness, chronic cough and excessive phlegm. An exacerbation can last up to several weeks and result in lung function decline, increased risk of death, and may be associated with severe anxiety.

Cigarette smoking is the leading cause of COPD, according to the National Heart, Lung, and Blood Institute. COPD is the fourth leading cause of death in the United States. [Read more…]

Filed Under: FDA News & Alerts, Smoking Tagged With: Chronic Cough, Chronic Obstructive Pulmonary Disease, copd, Daliresp, Forest Laboratories, Forest Pharmaceuticals, PDE-4, phosphodiesterase type 4, roflumilast

New Drug, Edarbi, Approved to Treat High Blood Pressure (Hypertension)

February 25, 2011 By MedNews Leave a Comment

The U.S. Food and Drug Administration today approved Edarbi tablets (azilsartan medoxomil) to treat high blood pressure (hypertension) in adults.

Data from clinical studies showed Edarbi to be more effective in lowering 24-hour blood pressure compared with two other FDA-approved hypertension drugs, Diovan (valsartan) and Benicar (olmesartan). [Read more…]

Filed Under: FDA News & Alerts, High Blood Pressure Tagged With: angiotensin II, azilsartan medoxomil, Edarbi, high blood pressure, hypertension, Takeda Pharmaceutical, vasopressor hormone

Test for Kidney Transplant Management Cleared by FDA

February 11, 2011 By MedNews Leave a Comment

The U.S. Food and Drug Administration today announced that it has cleared a test to help manage potential organ rejection in kidney transplant patients. The test, called QMS Everolimus Immunoassay, monitors the blood level of everolimus, a drug that helps prevent rejection in kidney transplants

Everolimus, marketed under the trade name Zortress, was approved by FDA in April 2010 for use in adult kidney transplant patients who are at low-to-moderate immunologic risk.. [Read more…]

Filed Under: FDA News & Alerts Tagged With: kidney, kidney transplant, kidneys

New Pacemaker Can Be Used Safely During MRI Exams

February 8, 2011 By MedNews Leave a Comment

The U.S. Food and Drug Administration today approved the first heart pacemaker designed to be used safely during certain magnetic resonance imaging (MRI) exams.

Pacemakers are surgically implanted medical devices that generate electrical impulses to treat irregular or stalled heart beats. MRIs use a powerful magnetic field, radio frequency pulses and an internal computer to produce detailed images of organs, soft tissues, bone, and other internal body structures not available with other imaging methods. [Read more…]

Filed Under: FDA News & Alerts, Heart Attack Tagged With: Inc., Medtronic, pacemaker, SureScan Pacing System

« Previous Page
Next Page »

Search



Tag Cloud

alcohol allergies alzheimers antibiotics breast cancer cancer Centers for Disease Control (CDC) children cholesterol dementia depression Diabetes diet drug abuse exercise fda flu food genetics geriatrics h1n1 heart heart attack heart disease high blood pressure HIV/AIDS hormone therapy hypertension lungs menopause NIH obesity pain pediatrics pregnancy prostate cancer seniors sleep smoking statistics stroke sun teens USA women's health

Recent Comments

  • Mia Fritz on Health Benefits of Dark Chocolate
  • Shilpa on Why Too Much Iron Can Be Dangerous
  • Racheal on Teen Pregnancy May Be Reduced by Sex Education in Schools, Says Study
  • Don on Prilosec, Nexium and Prevacid Tied to Higher Risk of Pneumonia
  • Meso on Brain Changes in Elderly Can Affect Mobility and Balance
  • About Us
  • Contact

Copyright © 2025 Mednews · Log in